NEWTON, Mass.--(BUSINESS WIRE)--Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, announced that today the Braman Family Breast Cancer Institute at the Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine, in collaboration with Medical University of South Carolina Hollings Cancer Center, is presenting a poster highlighting further positive results from an ongoing Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer at the AACR Breast Cancer Symposium in San Antonio, TX. Alberto Montero, MD, Assistant Professor of Medicine at Sylvester, is the Principal Investigator. The poster, Daily injections of the glutathione disulfide mimetic NOV-002 ameliorates hematologic toxicities from neoadjuvant chemotherapy in breast cancer patients enrolled in the NEO-NOVO trial, and significantly increases circulating dendritic cells, can be viewed at www.novelos.com ‘Our Products’, ‘NOV-002’ section. NOV-002 is also the subject of an ongoing pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track.
